Hundreds of suppliers bring hepatitis C medicines from India to Russia, but only M-PHARMA will help you buy sofosbuvir and daclatasvir and professional consultants will answer any questions you may have throughout the therapy.
A drug Fluvaxin- inactivated vaccine for the prevention of influenza.
Fluvaxin forms specific resistance to influenza viruses in 80-95% of those vaccinated.
Specific antibodies in protective titer are produced 10-15 days after vaccination and persist for at least 1 year. The high efficacy of the vaccine is ensured by the presence of both surface and internal antigens in it.
Indications for use:
Vaccine Fluvaxin intended for the prevention of influenza in adults and children over 6 months of age.
They vaccinate primarily people at high risk of developing post-influenza complications (suffering from chronic somatic diseases, often suffering from acute respiratory infections) or by the nature of their activities who have wide public contacts - medical personnel, teachers, workers in the service sector, transport. Vaccinations are carried out annually at the beginning of autumn. Vaccination is allowed at the beginning of the epidemic rise of influenza disease.
Mode of application:
Vaccine Fluvaxin injected intramuscularly or deeply subcutaneously once for adults and children over 3 years old at a dose of 0.5 ml, for children: from 6 months to 3 years at a dose of 0.25 ml.
Children under 8 years of age inclusive, who have not previously had the flu and who are vaccinated against influenza for the first time, are recommended to inject the vaccine twice with an interval of 4 weeks.
Before use, the vaccine must be brought to room temperature and shaken. The vaccine should not be used if there is color or foreign particles.
When using a vial containing 0.5 ml of vaccine for the immunization of children who are shown to administer 0.25 ml, it is necessary to draw all its contents into a syringe with the appropriate graduation and remove 0.25 ml of the vaccine.
The remainder of the vaccine must be destroyed immediately. A syringe containing 0.5 ml of the vaccine is not used to immunize children for whom 0.25 ml is indicated.
Side effects:
General reactions: fever, malaise, chills, fatigue, headache, sweating, myalgia, arthralgia.
Local reactions: hyperemia, swelling, soreness, bruising, induration at the injection site. These reactions are common but usually resolve within 1 to 2 days without special treatment. In rare cases, neuralgia (pain along the nerve), paresthesia, convulsions, short-term thrombocytopenia may be noted; allergic reactions including the development of anaphylactic shock; vasculitis with short-term kidney involvement (in extremely rare cases); neurological disorders.
Contraindications:
Contraindications to the use of the vaccine Fluvaxin are: hypersensitivity (including to chicken protein), a history of severe allergic reactions to vaccines. Diseases accompanied by an increase in body temperature (including acute manifestations of an infectious disease), exacerbation of chronic diseases. In these cases, vaccination should be postponed until recovery (remission). Against the background of mild ARVI, acute intestinal diseases, vaccination is carried out after the normalization of body temperature.
Pregnancy:
Vaccination decision Fluvaxin pregnant women should be taken by a doctor individually, taking into account the risk of contracting influenza and possible complications of influenza infection. The safest vaccination is in the P-III trimesters of pregnancy. There is currently no evidence of a possible risk to the fetus and impaired fertility when using the vaccine in the first 8 weeks of pregnancy, however, the appropriateness of vaccination during this period should be assessed by a doctor. Breastfeeding is not a contraindication for vaccination.
Interaction with other medicinal products:
Glucocorticosteroids and immunosuppressants reduce the immune response to the vaccine.
Fluvaxin can be administered on the same day with other vaccines (in different parts of the body), with the exception of BCG.
Storage conditions:
Transport and store in a dry, dark place at a temperature of 2 ° C to 8 ° C. Keep out of the reach of children.
Release form:
Fluvaxin - suspension for intramuscular and subcutaneous administration.
0.5 ml each in a bottle, sealed with a stopper under an aluminum roll and closed on top with a safety plastic cap. 0.25 ml and 0.5 ml each in a syringe, which is sealed in a glass foil blister.
5 vials or 1 syringe in a cardboard box with instructions for use.
Composition:
Fluvaxin contains active ingredient: Vaccine for the prevention of influenza (inactivated).
Additionally:
Intravascular administration is not allowed. The doctor should be informed about any treatment that coincides with the vaccination, or about the recent use of any drugs (including over-the-counter), as well as about the patient's immunodeficiency, allergy, or an unusual reaction to a previous vaccination.
In the offices where vaccination is carried out, it is necessary to have medicines for carrying out anti-shock measures and stopping anaphylactic reaction. The vaccinated person must be under the supervision of a health worker for 30 minutes after immunization.
Source: www.medcentre24.ru
Release form
Suspension for intramuscular and subcutaneous administration of Fluvaxin - 0.5 ml in a vial, sealed with a stopper under an aluminum roll and closed on top with a protective plastic cap. 0.25 ml and 0.5 ml each in a syringe, which is sealed in a glass foil blister.
5 vials or 1 syringe in a cardboard box with instructions for use.
INN
Inactivated vaccine for the prevention of influenza
Group
Antimicrobials for systemic use
Pharmgroup
Antiviral vaccines
Pharmaceutical subgroup
Influenza vaccines
Description
Colorless slightly opalescent liquid.
The action of the drug Fluvaxin suspension for intramuscular and subcutaneous administration
Characteristics: Influenza trivalent polymer-subunit liquid vaccine representing surface glycoproteins (hemagglutinin and neuraminidase) isolated from purified influenza A and B viruses in combination with polyoxidonium. One immunizing dose (0.5 ml) contains 5 μg of hemagglutinin of influenza A (H1N1), A (H3N2) strains, 11 μg of influenza B virus and 500 μg of polyoxidonium. Highly purified preparation, free from impurities of non-virionic origin. Preservative - merthiolate from 85 to 115 μg / ml. The antigenic composition of the vaccine changes every year in accordance with the epidemic situation and WHO recommendations.
Immunological properties
Fluvaxin forms specific resistance to influenza viruses in 80 - 95% of those vaccinated. Specific antibodies in protective titer are produced 10 to 15 days after vaccination and persist for at least 1 year. The high efficacy of the vaccine is ensured by the presence of both surface and internal antigens in it.
The inclusion of an immunomodulator polyoxidonium in a vaccine preparation provides an increase in the immunogenicity and stability of antigens, improves immunological memory, significantly reduces the vaccination dose of antigens, and increases the body's resistance to other infections by correcting the immune status.
Indications for use
Influenza - active preventive immunization of children from 6 months, adolescents and adults from risk groups: people over 60 years old, people with chronic somatic diseases, often suffering from acute respiratory infections, preschool children, schoolchildren, medical workers, workers in the service sector, transport, educational institutions, military personnel.
Contraindications
Hypersensitivity, incl. to chicken protein, allergic reactions to the previous administration of the vaccine, acute feverish conditions or exacerbation of a chronic disease (vaccination is carried out after recovery or remission), mild ARVI (vaccination is carried out after normalization of body temperature).
Pregnancy and lactation
The decision to vaccinate pregnant women should be made by the doctor individually, taking into account the risk of contracting influenza and possible complications of influenza infection. The safest vaccination is in the II-III trimesters of pregnancy. There is currently no evidence of a possible risk to the fetus and impaired fertility when using the vaccine in the first 8 weeks of pregnancy, however, the appropriateness of vaccination during this period should be assessed by a doctor. Breastfeeding is not a contraindication for vaccination.
Method of administration and dosage
The Fluvaxin vaccine is administered intramuscularly or deeply subcutaneously once for adults and children over 3 years old at a dose of 0.5 ml, for children: from 6 months. up to 3 years at a dose of 0.25 ml. Children under 8 years old, inclusive, who have not previously had the flu and who are being vaccinated against influenza for the first time, are recommended to inject the vaccine twice with an interval of 4 weeks. Before use, the vaccine must be brought to room temperature and shaken. The vaccine should not be used if there is color or foreign particles.
When using a vial containing 0.5 ml of vaccine for the immunization of children who are shown to administer 0.25 ml, it is necessary to draw all its contents into a syringe with the appropriate graduation and remove 0.25 ml of the vaccine. The remainder of the vaccine must be destroyed immediately. A syringe containing 0.5 ml of the vaccine is not used to immunize children for whom 0.25 ml is indicated.
Side effects
Local reactions: soreness, swelling and flushing of the skin.
General reactions (usually disappear on their own after 1-2 days): malaise, headache, weakness, subfebrile condition. Rarely - allergic reactions.
Interaction with other drugs
The vaccine can be administered against the background of basic therapy for the underlying disease.
The vaccine can be used simultaneously with other inactivated vaccines (in this case, contraindications to each of the vaccines used should be taken into account, the drugs should be injected into different parts of the body, using different syringes).
special instructions
Vaccination is carried out annually in the autumn-winter period. Vaccination is possible at the beginning of an epidemic rise in the incidence of influenza.
Do not give IV. Vaccination sites should be equipped with anti-shock therapy.
The vaccinated person must be monitored by a health worker for 30 minutes after immunization.
The opening of the ampoules and the vaccination procedure are carried out in strict observance of the rules of asepsis and antiseptics: before opening the ampoule knife, wipe the ampoule neck with cotton wool moistened with 70% ethanol, open the ampoule, draw the vaccine into a disposable syringe and remove excess air from the syringe. Ethanol is rubbed onto the skin at the injection site.
The drug in the opened ampoule is not subject to storage.
On the day of vaccination, the vaccinated must be examined by a doctor (paramedic) with mandatory thermometry. At a body temperature above 37 degrees C, vaccination is not carried out.
The drug is not suitable for use in ampoules with impaired integrity or labeling, with a change in physical properties (color, transparency), with an expired shelf life, in violation of the requirements for storage conditions.
Vaccination of patients receiving immunosuppressive therapy may be less effective.
Shelf life
1 year. Do not use after the expiration date printed on the package.
A drug Fluvaxin- inactivated vaccine for the prevention of influenza.
Fluvaxin forms specific resistance to influenza viruses in 80-95% of those vaccinated.
Specific antibodies in protective titer are produced 10-15 days after vaccination and persist for at least 1 year. The high efficacy of the vaccine is ensured by the presence of both surface and internal antigens in it.
Indications for use:
Vaccine Fluvaxin intended for the prevention of influenza in adults and children over 6 months of age.
They vaccinate primarily people at high risk of developing post-influenza complications (suffering from chronic somatic diseases, often suffering from acute respiratory infections) or by the nature of their activities who have wide public contacts - medical personnel, teachers, workers in the service sector, transport. Vaccinations are carried out annually at the beginning of autumn. Vaccination is allowed at the beginning of the epidemic rise of influenza disease.
Mode of application:
Vaccine Fluvaxin injected intramuscularly or deeply subcutaneously once for adults and children over 3 years old at a dose of 0.5 ml, for children: from 6 months to 3 years at a dose of 0.25 ml.
Children under 8 years of age inclusive, who have not previously had the flu and who are vaccinated against influenza for the first time, are recommended to inject the vaccine twice with an interval of 4 weeks.
Before use, the vaccine must be brought to room temperature and shaken. The vaccine should not be used if there is color or foreign particles.
When using a vial containing 0.5 ml of vaccine for the immunization of children who are shown to administer 0.25 ml, it is necessary to draw all its contents into a syringe with the appropriate graduation and remove 0.25 ml of the vaccine.
The remainder of the vaccine must be destroyed immediately. A syringe containing 0.5 ml of the vaccine is not used to immunize children for whom 0.25 ml is indicated.
Side effects:
General reactions: fever, malaise, chills, fatigue, headache, sweating, myalgia, arthralgia. Local reactions: hyperemia, swelling, soreness, bruising, induration at the injection site. These reactions are common but usually resolve within 1 to 2 days without special treatment. In rare cases, neuralgia (pain along the nerve), paresthesia, convulsions, short-term thrombocytopenia may be noted; allergic reactions including the development of anaphylactic shock; vasculitis with short-term kidney involvement (in extremely rare cases); neurological disorders.
Contraindications:
Contraindications to the use of the vaccine Fluvaxin are: hypersensitivity (including to chicken protein), a history of severe allergic reactions to vaccines. Diseases accompanied by an increase in body temperature (including acute manifestations of an infectious disease), exacerbation of chronic diseases. In these cases, vaccination should be postponed until recovery (remission). Against the background of mild ARVI, acute intestinal diseases, vaccination is carried out after the normalization of body temperature.
Pregnancy:
Vaccination decision Fluvaxin pregnant women should be taken by a doctor individually, taking into account the risk of contracting influenza and possible complications of influenza infection. The safest vaccination is in the P-III trimesters of pregnancy. There is currently no evidence of a possible risk to the fetus and impaired fertility when using the vaccine in the first 8 weeks of pregnancy, however, the appropriateness of vaccination during this period should be assessed by a doctor. Breastfeeding is not a contraindication for vaccination.
Interaction with other medicinal products:
Glucocorticosteroids and immunosuppressants reduce the immune response to the vaccine.
Fluvaxin can be administered on the same day with other vaccines (in different parts of the body), with the exception of BCG.
Storage conditions:
Transport and store in a dry, dark place at a temperature of 2 ° C to 8 ° C. Keep out of the reach of children.
Release form:
Fluvaxin - suspension for intramuscular and subcutaneous administration.
0.5 ml each in a bottle, sealed with a stopper under an aluminum roll and closed on top with a safety plastic cap. 0.25 ml and 0.5 ml each in a syringe, which is sealed in a glass foil blister.
5 vials or 1 syringe in a cardboard box with instructions for use.
Composition:
Fluvaxin contains active ingredient: Vaccine for the prevention of influenza (inactivated).
Additionally:
Intravascular administration is not allowed. The doctor should be informed about any treatment that coincides with the vaccination, or about the recent use of any drugs (including over-the-counter), as well as about the patient's immunodeficiency, allergy, or an unusual reaction to a previous vaccination.
In the offices where vaccination is carried out, it is necessary to have medicines for carrying out anti-shock measures and stopping anaphylactic reaction. The vaccinated person must be under the supervision of a health worker for 30 minutes after immunization.
suspension for intramuscular and subcutaneous administration
Composition:0.5 ml of the drug contains:
active substances: influenza viruses cultured in chicken embryos, inactivated, cleaved, represented by strains equivalent to the following:
A (H1N1) strain * 15mkg hemagglutigin
A
(H 3 N 2) strain * 15μg hemagglutiginB strain * 15μg hemagglutigin
* Indicates the strains used for this epidemic season.
Excipients: thiomersal (preservative), sodium chloride, potassium chloride, potassium dihydrogen phosphate, sodium hydrogen phosphate, water for injection. trace amounts: formaldehyde, otoxinol-9.
Description: Colorless slightly opalescent liquid Pharmacotherapeutic group: MIBP - ATX vaccine: & nbspJ.07.B.B.01 Influenza Virus - Inactivated Whole Virus
J.07.B.B Flu vaccine
Pharmacodynamics:Immunological propertiesFluvaxin forms specific resistance to influenza viruses in 80-95% of those vaccinated. Specific antibodies in protective titer are produced 10-15 days after vaccination and persist for at least 1 year. High efficiency
b the vaccine is ensured by the presence of both superficial and internal antigens. Indications:Prevention of influenza in adults and children over 6 month They vaccinate primarily people at high risk of developing post-influenza complications (suffering from chronic somatic diseases, often suffering from acute respiratory infections) or by the nature of their activities who have wide public contacts - medical personnel, teachers, workers in the service sector, transport. Vaccinations are carried out annually at the beginning of autumn. Vaccination is allowed at the beginning of the epidemic rise of influenza disease.
Contraindications:Hypersensitivity (including chicken protein), a history of severe allergic reactions to vaccines. Diseases accompanied by an increase in body temperature (including acute manifestations of an infectious disease), exacerbation of chronic diseases. In these cases, vaccination should be postponed until recovery (remission). Against the background of mild ARVI, acute intestinal diseases, vaccination is carried out after the normalization of body temperature.
Pregnancy and lactation:The decision to vaccinate pregnant women must be made by a doctor.
individually, taking into account the risk of influenza infection and possible complications of influenza infection. The safest vaccination is in the P-III trimesters of pregnancy. There is currently no evidence of a possible risk to the fetus and impaired fertility when using the vaccine in the first 8 weeks of pregnancy, however, the appropriateness of vaccination during this period should be assessed by a doctor. Breastfeeding is not a contraindication for vaccination.
Method of administration and dosage:The vaccine is administered intramuscularly or deeply subcutaneously once for adults and children over 3 years old at a dose of 0.5 ml, for children: with 6 months to 3 years at a dose of 0.25 ml. Children up to 8 years inclusive, previously not sick with influenza and being vaccinated against influenza for the first time, it is recommended to administer the vaccine twice with an interval of 4 weeks. Before use, the vaccine must be brought to room temperature and shaken. The vaccine should not be used if there is color or foreign particles.
When using a vial containing 0.5 ml of vaccine for the immunization of children who are shown to administer 0.25 ml, it is necessary to draw all its contents into a syringe with the appropriate graduation and remove 0.25 ml of the vaccine. The remainder of the vaccine must be destroyed immediately. A syringe containing 0.5 ml of the vaccine is not used to immunize children for whom 0.25 ml is indicated.
Side effects:General reactions: fever, malaise, chills, fatigue, headache, sweating, myalgia, arthralgia. Local reactions: hyperemia, swelling, soreness, bruising, induration at the injection site. These reactions are common but usually resolve within 1 to 2 days without special treatment. In rare cases, neuralgia (pain along the nerve), paresthesia, convulsions, short-term thrombocytopenia may be noted; allergic reactions including the development of anaphylactic shock; vasculitis with short-term kidney involvement (in extremely rare cases); neurological disorders.
Interaction:Glucocorticosteroids and immunosuppressants reduce the immune response to the vaccine. Fluvaxin can be given on the same day as other vaccines (in different parts of the body), with the exception of BCG.
Special instructions:Intravascular administration is not allowed. The doctor should be informed about any treatment that coincides with the vaccination, or about the recent use of any drugs (including over-the-counter), as well as about the patient's immunodeficiency, allergy, or an unusual reaction to a previous vaccination.
In the offices where vaccination is carried out, it is necessary to have medicines for carrying out anti-shock measures and stopping anaphylactic reaction. The vaccinated person must be under the supervision of a health worker for 30 minutes after immunization.
Release form / dosage:Suspension for intramuscular and subcutaneous administration.
Package: 0.5 ml each in a bottle, sealed with a stopper under an aluminum roll and closed on top with a safety plastic cap. 0.25 ml and 0.5 ml each in a syringe, which is sealed in a glass foil blister.5 vials or 1 syringe in a cardboard box with instructions for use.
Storage conditions:Transportation and storage conditions.
Influenza is a disease that affects all age categories: from newborns to the elderly. A special category is made up of persons who have close and long-term contact with the population (medical workers, service industries, teachers, etc.). This group is at high risk of getting the flu. The virus is extremely toxic and is excreted by a sick person throughout the entire period of the disease.
Fluvaxin - a drug for the prevention of influenza (photo: www.medcentre24.ru)
The transmission mechanism is airborne: when talking, kissing or coughing. It is characterized by fever, malaise, weakness, cough, nasal discharge, chills, muscle and joint pain. Duration - from 5 days to 10. After suffering an illness, weakness and fatigue persist for some time. For effective prevention, an inactivated vaccine, Fluvaxin, is used.
Composition and form of release
Fluvaxin is a liquid suspension for intramuscular or deep subcutaneous injection. Available in 0.5 ml vials or in 0.5 ml or 0.25 ml syringes.
Composition of one dose (0.5 ml):
- Inactivated virus strain type A (H1N1) - 15 μg.
- Inactivated virus strain type A (H3N2) - 15 μg.
- Inactivated strain of virus type B - 15 μg.
- Additionally: Sodium chloride, potassium chloride, thiomersal.
- Traces: formaldehyde.
The sale goes on 1 syringe or 5 vials in a package with instructions for use and storage.
Release form - vials or individual syringes (photo: www.hipolabor.com.)
Pharmacological action (drug characteristics)
Fluvaxin, due to the presence of hemagglutinins in the composition, forms a strong immunity against the influenza virus. This is due to the formation in the human body of protective antibodies to the pathological pathogen. The highest concentration of protective cells is formed on the 7th day after the administration of the vaccine. The vaccine has a wide spectrum of action against influenza A and B. Due to the presence of additional substances such as thiomersal in the composition, immunity remains in the human body for 1 year. When the drug is injected into the human body, protective forces activate both cellular protection mechanisms and humoral ones. A stable (for 350 days) and specific (against the influenza virus) immunity is formed. People who were vaccinated before the outbreak show a high resistance to the onset of the disease and its complications.
Indications for vaccine administration (complex preparation)
The drug is allowed to be administered to children from six months and adults of all ages.
The introduction of the vaccine is indicated for such groups of the population:
- Seniors (over 65).
- Children from 6 months of age.
- Persons whose activities are associated with close and long-term work with other people (workers in the service sector and medical institutions, educators and teachers, military personnel).
- People suffering from chronic diseases of the nervous, respiratory, endocrine and digestive systems.
- Children of preschool and school age.
- Persons who often suffer from acute viral diseases.
- Patients with cancer.
- People with autoimmune diseases.
- Persons who are going to travel to an area with a high incidence of influenza.
No additional or special training is provided prior to immunization.
Doctor's advice! If you are shown the introduction of a vaccine, then you should not postpone this process. The drug should be used before the beginning of the epidemic process - the beginning or the middle of autumn. This is due to the fact that after vaccination, immunity is formed for some time, and with the onset of widespread influenza, the body will be ready to "fight" the virus.
Method of administration and dosage
Route of administration: deeply subcutaneously or intramuscularly into the outer surface of the upper third of the shoulder (for adults) or into the upper front part of the thigh (for children under 3 years of age).
Intramuscular administration is prohibited, as there are undesirable and dangerous consequences.
One dose is 0.5 ml or 0.25 ml, depending on the age of the vaccinated:
- For children under 3 years of age, a dose of 0.25 ml is used.
- Adults and children over three years of age - 0.5 ml.
Important! Children under 8 years old who have not been vaccinated against influenza before, the drug is administered twice with an interval of one month. This group is subject to observation, since the use of such a drug was carried out for the first time and it is difficult to predict the child's reaction.
If the dose is 0.25 ml, and in the vial is 0.5 ml, then it is necessary to draw the entire contents into a syringe, and then remove the unnecessary amount of the drug.
Syringes are used that contain either the full dose or half of it. Such management facilitates the work of medical personnel and excludes the occurrence of adverse reactions and complications.
Before using the drug, carefully inspect the packaging, vial or syringe for damage, discoloration or consistency of the vaccine. If there are changes, it is necessary to inform the head physician and stop the immunization. The vial is shaken and kept for several minutes at room temperature immediately before administration.
Special Notes
Vaccination is a responsible process that requires preparation: a doctor's examination and the delivery of basic laboratory and instrumental parameters. Such measures are applied to exclude acute or chronic conditions that lead to complications or adverse reactions after drug administration. The peak of the spread of influenza among the population falls at the beginning of winter, so immunization begins in September or October.
Vaccinations are carried out in specially equipped rooms of schools, clinics, kindergartens and hospitals. Vaccination sites include a refrigerator for storing drugs, a medicine cabinet for emergency care, a sterile table, a couch, a table and chairs.
The administration of the drug is carried out with the strict application of the rules of asepsis and antiseptics. In the presence of damage to the packaging or vial (syringe), use of the vaccine is prohibited. If the expiration date has expired, the vaccination is contraindicated.
Side effects
The occurrence of undesirable reactions is rare and is associated with individual intolerance to the components of the drug or violation of transportation rules. There is also a risk in people who have previously experienced negative reactions to the administration of drugs in this group.
Adverse reactions are systemic in nature (headache, dizziness, weakness, malaise, fever). There are also local manifestations (rash or redness at the injection site, hemorrhage, soreness).
If any unexpected reactions occur, you need to see a doctor for help or call an ambulance.
Contraindications for vaccine administration
There are relative (the introduction of the drug is determined by the doctor individually) and absolute (the use of vaccination is strictly prohibited) contraindications.
The first group includes:
- Pregnancy and breastfeeding.
- Chronic disease in remission.
- Temperature increase.
- Weakness and malaise.
Breastfeeding is a relative contraindication (photo: www.otvetymamam.ru)
The second group of contraindications includes:
- When previous cases of vaccine administration caused severe complications.
- Acute diseases.
- Individual intolerance to the components of the vaccine.
- Insufficient immune system (AIDS).
Pregnancy and lactation with the administration of Fluvaxin
The doctor individually decides whether to vaccinate a pregnant woman or during lactation. There are many studies that prove the vaccine is safe for this population.
Interaction with other medicinal products
It is forbidden to use in conjunction with other vaccines on the same day. In some cases, grafting is allowed, but in different parts of the body. Not recommended for use with drugs that reduce the body's defenses - glucocorticoids and immunosuppressants.
Storage conditions of the drug
The vaccine is stored in refrigeration units at temperatures ranging from 2 to 8 degrees Celsius. The place is protected from sunlight. Transportation is carried out under conditions similar to those used during storage.
Shelf life is 1 year.
Post-vaccination period
After immunization, the patient is present at a medical facility for half an hour, as a local reaction or anaphylactic shock may occur. In this case, the doctor will provide emergency care and prevent the occurrence of other complications.
Fluvaxin's analogs
There are many inactivated flu vaccines on the pharmaceutical market. The differences lie only in the duration of the formed immunity and the country of origin.
The following identical drugs widespread in our country:
- Agrippal.
- Vaxigripp.
- Influvac.
- Padeflu.
- Influvir.
Vaxigripp is an analogue of Fluvaxin (photo: www.ishim.bezformata.ru)
Important! Only a doctor prescribes the necessary and effective vaccination in a particular case. It is forbidden to independently approach the choice of the drug. Only a specialist will compare all indications and contraindications in a particular case and choose the best option. The above circumstances will exclude the occurrence of unforeseen complications and side effects.
Loading ...